This cross-sectional study was conducted on infants who applied to Malatya Training and Research Hospital neonatal hearing screening service and passed the screening ABR. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was conducted after obtaining approval of the Ministry of Health in Turkey and approval of the ethics committee in Malatya Clinical Research Ethics (Ethical number 2020/207) before the study. Thirty-seven infants whose mother was pregnant between March 2020 and December 2020 and were born after the diagnosis of COVID- 19 during pregnancy and 36 healthy infants whose mother had no diagnosis of COVID-19 or other disease during her pregnancy were included in the study. Birth weight, maternal age, gender, type of delivery were recorded for all participants and the trimester of pregnancy of the mother during the period of COVID-19, fever, cough, shortness of breath, olfactory dysfunctions, diarrhea, myalgia, headache, runny nose, sore throat symptoms were questioned in the patient group. A detailed ear, nose and throat examination was performed for all infants included in the study before the test. Tympanogram and acoustic reflexes were obtained for both ears with 226 Hz probe tone frequency in all participants. Infants with diseases related to the outer ear and middle ear, those who have not undergone neonatal hearing screening, subjects who have received postnatal intensive care treatment, participants who have hereditary hearing loss in their family, those whose mother had TORCH group infection during pregnancy, infants with auricular and external auditory canal anomalies, those with a birth weight below 1500 g, babies born before 37th week and with hyperbilirubinemia requiring hospitalization were excluded from the study. Transient evoked otoacoustic emission (TEOAE), Distortion Product Otoacoustic Emission (DPOAE) and Contralateral Suppression of OAE (CLS OAE) tests were performed on all infants. All audiologic measurements were performed in a sound-proof room. The present study was carried out in a blind manner that the audiologist who performed the OAEs was not informed whether the babies were patient or healthy control. Inclusion criteria were infants with type A tympanogram, normal neonatal hearing screening ABR bilaterally, and had no additional disease. Written informed consent was obtained from all participating parents.

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.